Zonisamide

68291-97-4

C8H8N2O3S

DMSO : >= 100 mg/mL (471.19 mM); H2O : 0.67 mg/mL (3.16 mM; Need ultrasonic)

Membrane Transporter/Ion Channel; Membrane Transporter/Ion Channel; Neuronal Signaling

Zonisamide is a 1, 2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug. Target: Calcium channel inhibitor; Sodium channel inhibitor Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures for adults; infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide is a 1, 2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug. It has shown activity in various animal models of epilepsy, and although a detailed mode of action awaits clarification it appears to block the propagation/spread of seizure discharges and to suppress the epileptogenic focus [1]. Zonisamide 500 mg/day was significantly superior to placebo in reducing the frequency of complex partial seizures (-51% versus -16%), all partial seizures and all seizures, with dose-dependent benefit provided over a 100-500 mg/day dose range. Supporting trials have confirmed significant increases in reduction in median seizure frequency (up to 41%) and responder rates (35-42%) compared with placebo following zonisamide 400-600 mg/day, enabling 20-27% of patients to attain >or=75% reduction in seizure frequency [2]. Clinical indications: Epilepsy; Lewy body dementia; Parkinsons disease Toxicity: Anorexia; Somnolence; Dizziness; Irritability; Confusional state; Depression; Diplopia; Memory impairment